Cipher Pharmaceuticals Inc. (TSX: CPH)
Health Care · Pharmaceuticals · CA
CA$13.65
0.00% today · -6.3% 1Y
Cipher Pharmaceuticals Inc. (TSX: CPH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $243.14M and employs 5 people.
Over the last twelve months the share price has lost 6.3%, trading between 12.48 and 20.56.
Tweenvest scores Cipher Pharmaceuticals Inc. across four factors: quality 78/100, value 50/100, growth 80/100. Its strongest factor is growth.
CPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $243.14M
- Revenue (TTM)
- $49.62M
- P/E
- 8.56
- EPS
- 1.12
- Dividend yield
- —
- Beta (5Y)
- 0.41
- 52-week high
- CA$20.56
- 52-week low
- CA$12.48
- Avg volume (3M)
- —
- Shares outstanding
- 25.42M
- Employees
- 5
- Next earnings
- —
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
- ISIN
- CA17253X1050
- Founded
- 2000
- Listed since
- May 7, 2004
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Jacobson Pharma Corporation LimitedSEHK: 2633 | $247.24M | HK$0.97 | -0.51% |
| Ginwa Enterprise (Group) Inc.SHSE: 600080 | $246.39M | CN¥4.63 | +0.43% |
| AnnJi Pharmaceutical Co., Ltd.TPEX: 7754 | $245.60M | NT$77.80 | -0.26% |
| Laboratorio Reig Jofre, S.A.BME: RJF | $243.53M | €2.62 | -1.13% |
| Auxly Cannabis Group Inc.TSX: XLY | $241.66M | CA$3.34 | +2.45% |
| Cresco Labs Inc.CNSX: CL | $239.19M | CA$0.92 | -3.16% |
| SIGA Technologies, Inc.NasdaqGM: SIGA | $235.67M | $3.17 | -3.51% |
| Daito Pharmaceutical Co.,Ltd.TSE: 4577 | $235.23M | ¥1,318.00 | +0.69% |
Figures last refreshed Oct 11, 2026.